Article Information
History
- August 31, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Thibaud Coroller1,⋈,
- Berkman Sahiner2,⋈,
- Anup Amatya3,†,
- Alexej Gossmann2,†,
- Konstantinos Karagiannis4,†,
- Ravi K. Samala2,†,
- Luis Santana-Quintero4,†,
- Nadia Solovieff1,†,
- Craig Wang5,†,
- Laleh Amiri-Kordestani6,
- Qian Cao2,
- Kenny H. Cha2,
- Rosane Charlab Orbach3,
- Frank H. Cross Jr.3,
- Tingting Hu2,
- Ruihao Huang3,
- Jeffrey Kraft3,
- Peter Krusche5,
- Yutong Li1,
- Zheng Li1,
- Ilya Mazo4,
- Conor Moloney5,
- Rahul Paul4,
- Jason Plawinski5,
- Susan Schnakenberg1,
- Paolo Serra1,
- Sean Smith4,
- Chi Song3,
- Fei Su1,
- Sajanth Subramaniam5,
- Mohit Tiwari3,
- Colin Vechery1,
- Xin Xiong2,
- Juan Pablo Zarate1,
- Jonathan Ziegler5,
- Hao Zhu3,
- Arunava Chakravartty1,‡@,
- Qi Liu3,‡,
- David Ohlssen1,‡,
- Nicholas Petrick2,‡,
- Julie A. Schneider7,‡@,
- Mark Walderhaug4,‡ and
- Emmanuel Zuber5,‡
- 1Novartis Pharmaceutical Company, USA
- 2Center for Devices and Radiological Health, U.S. Food & Drug Administration, USA
- 3Center for Drug Evaluation and Research, U.S. Food & Drug Administration, USA
- 4Center for Biologics Evaluation and Research, U.S. Food & Drug Administration, USA
- 5Novartis Pharma AG, Switzerland
- 6Office of Oncologic Drugs, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA
- 7Oncology Center of Excellence, U.S. Food & Drug Administration, USA
- ↵@Corresponding authors: arunava.chakravartty{at}novartis.com, julie.schneider{at}fda.hhs.gov